A phase 1, open-label, multi-dose, dose escalation and expansion study to investigate the safety, tolerability, pharmacokinetics and anti-tumor activities of CS3002, a CDK4/6 inhibitor, in subjects with advance solid tumors

  • Park, John (Primary Chief Investigator)
  • Sabanathan, Dhanusha, (Associate Investigator)
  • Chapman, Nicola, (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymCS3002-101
StatusActive
Effective start/end date30/10/2024/09/25